Upstream Bio
Upstream Bio
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
About
Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases. Their lead program is a monoclonal antibody designed to inhibit the TSLP receptor, a key upstream mediator in multiple inflammatory signaling pathways. By targeting TSLP, Upstream Bio aims to address a broad range of immune-mediated conditions. Teams look it up for Life Sciences, Therapeutics, Biotech.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
